Snap-8

Third-Party Tested

Independent lab verified

Batch-Specific CoA

Publicly accessible

YPB.272

Reference number

10mg

Lyophilized vial

Origin

Snap-8 (acetyl octapeptide-3) was developed by Lipotec (now part of Lubrizol/Berkshire Hathaway) as an extension of the earlier hexapeptide Argireline (acetyl hexapeptide-3). Both compounds were designed as topical neurocosmetic peptides based on the SNAP-25 protein sequence, which is a component of the neuronal SNARE complex involved in neurotransmitter release.

Research Lineage

The development was based on research into botulinum toxin's mechanism of action — specifically, the cleavage of SNAP-25 that prevents vesicle fusion. Lipotec's approach was to create peptide fragments that could compete with native SNAP-25 for SNARE complex assembly. Published studies are primarily from Lipotec's in-house research and independent cosmetic science evaluations.

Mechanism of Action

Snap-8 is proposed to modulate SNARE complex formation by competing with native SNAP-25 for binding to syntaxin and VAMP. In cell culture models, this competition has been observed to reduce vesicle fusion efficiency and neurotransmitter release at the neuromuscular junction. The mechanism is distinct from botulinum toxin, which cleaves SNAP-25 irreversibly. Topical application studies have measured effects on skin surface appearance.

Structural Notes

Acetylated octapeptide. Sequence: Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2. Molecular weight: 1075.16 Da. Extension of the Argireline hexapeptide sequence with two additional N-terminal residues.